Peregrine Pharmaceuticals (PPHM +9.1%) moves up after its FQ1 beat estimates across the board on...

|About: Peregrine Pharmaceuticals Inc. (PPHM)|By:, SA News Editor

Peregrine Pharmaceuticals (PPHM +9.1%) moves up after its FQ1 beat estimates across the board on fewer than anticipated losses, despite a double digit Y/Y decline in total revenue. The stock soared on Friday, after the company said a recent Phase IIb trial of its lung cancer treatment bavituximab produced interim data showing statistically significant improvement in overall survival.